Results 201 to 210 of about 10,214,758 (341)

Recent Developments in Nanoparticle‐Hydrogel Hybrid Materials for Controlled Release

Advanced Science, EarlyView.
This review highlights recent advances in nanoparticle–hydrogel hybrid materials for controlled drug delivery. It explores diverse nanocarrier–hydrogel combinations, drug loading strategies, release mechanisms, and stimuli‐responsive behaviors. Emphasis is placed on the molecular interactions driving hybrid material performance, offering insights into ...
Yiping Fan, Qi Han, Haiyan Li, Xudong Cai, Brendan Dyett, Ruirui Qiao, Calum J. Drummond, San H. Thang, Jiali Zhai   +8 more
wiley   +1 more source

Measuring and Targeting Persistent Inflammation in Chronic Coronary Disease. [PDF]

JACC Adv
Frangogiannis NG.
europepmc   +1 more source

Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCI. [PDF]

EuroIntervention, 2023
Kotoku N, Ninomiya K, Masuda S, O'Leary N, Garg S, Naito M, Miyashita K, Tobe A, Kageyama S, Tsai TY, Revaiah PC, Tu S, Kozuma K, Kawashima H, Ishibashi Y, Nakazawa G, Takahashi K, Okamura T, Miyazaki Y, Tateishi H, Nakamura M, Kogame N, Asano T, Nakatani S, Morino Y, Ishida M, Katagiri Y, Ono M, Hara H, Sotomi Y, Tanabe K, Ozaki Y, Muramatsu T, Dijkstra J, Onuma Y, Serruys PW.   +35 more
europepmc   +1 more source

ALKBH5‐Mediated M6A Demethylation of G3BP1 Attenuates Ferroptosis Via Cytoplasmic Retention of YBX1/p53 in Diabetic Myocardial Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
ALKBH5 promoted G3BP1 expression via m⁶A methylation at sites 142/173. G3BP1 interacts with YBX1 and p53, reducing their nuclear translocation and decreasing p53‐mediated SLC7A11 repression. This inhibites cardiomyocyte ferroptosis and mitigates myocardial damage during diabetic ischemia‐reperfusion injury.
Wenyuan Li, Wei Li, Yan Leng, Heng Xu, Zhongyuan Xia, Yao Wang   +5 more
wiley   +1 more source

Association of Circulating Phenylacetylglutamine With Multi-Vessel Coronary Disease Severity and Outcomes in ST-Segment-Elevation Myocardial Infarction. [PDF]

J Am Heart Assoc
Zhao P, Dong N, Wang Y, Zhao S, Tian Y, Qin Z, Ban X, Han F, Meng L, Yang F, Wang Y, Wu Y, Yu Z, Xu Q, Li X, Li S, Liu H, Fang S, Xie W, Yu B, Liu X, Tian J.   +21 more
europepmc   +1 more source

Dietary Composition, Angiographic Coronary Disease, and Cardiovascular Outcomes in the WISE Study (Women's Ischemia Syndrome Evaluation). [PDF]

J Clin Med, 2023
Schwartz BH, Choi SY, Mathews A, Aggarwal M, Handberg EM, Pepine CJ, Rogers W, Reis S, Cook-Wiens G, Merz CNB, Wei J.   +10 more
europepmc   +1 more source

Loss of Hepatic Angiotensinogen Attenuates Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction

Advanced Science, EarlyView.
Increased hepatic angiotensinogen (AGT) abundance leads to cardiac diastolic dysfunction via the AngII‐independent pathway. Liver‐derived AGT is internalized by LRP2 in cardiac endothelial cells, subsequently contributing to myocardial diastolic dysfunction by suppressing microvascular angiogenesis via inhibiting the GATA2/Pim3 pathway.
Zetao Heng, Min Hong, Zhaocai Zhang, Ximing Ye, Jianan Zhou, Wentao Wu, Jiabing Rong, Yinchuan Xu   +7 more
wiley   +1 more source

Changes in coronary disease management decisions in real-world practice between 2015 and 2023: insights from the EVAREST/BSE-NSTEP observational study. [PDF]

Eur Heart J Cardiovasc Imaging
Johnson CL, Krasner S, Woodward W, Mao E, McCourt A, Dockerill C, Balkhausen K, Chandrasekaran B, Kardos A, Sabharwal N, Firoozan S, Sarwar R, Senior R, Sharma R, Wong K, Augustine DX, Paton M, O'Driscoll J, Oxborough D, Pearce K, Robinson S, Willis J, Leeson P, EVAREST/BSE-NSTEP Investigators.   +23 more
europepmc   +1 more source

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

New England Journal of Medicine, 1998
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew J Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, Lucy A. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly   +98 more
semanticscholar   +1 more source

Atrial Fibroblasts‐Derived Extracellular Vesicles Exacerbate Atrial Arrhythmogenesis

Advanced Science, EarlyView.
Exosome miR‐224‐5p derived from angiotensin II‐treated atrial fibroblasts creates a substrate for AF by promoting atrial electrical remodeling. Increased exosome miR‐224‐5p enhances AF susceptibility by inhibiting CACNA1c expression and decreasing ICa current of atrial cardiomyocytes.
Yue Yuan, Xinbo Zhao, Xuejie Han, Yukai Cao, Xuexin Jin, Ling Shi, Xin Bi, Desheng Li, Yun Zhang, Wenbo Ma, Jiahui Song, Zhenwei Pan, Zhiren Zhang, Yue Li   +13 more
wiley   +1 more source